Place of NCMAG in cancer medicines governance v2.0

- MEDICINE / REGIMEN
- CLINICAL TRIAL DATA
  - Monitor
  - Benefit-harm analysis
- REGULATOR (MHRA)
  - Quality
  - Specified dosing and patient group
- ON-LABEL USE
- HTA ADVICE (SMC)
  - Recommendation

- OFF-LABEL USE OF LICENSED PRODUCT
  - Benefit-risk balance not assessed by regulator

- HEALTH BOARD GOVERNANCE
  - Clinical evidence gathering
  - Local decision-making

- NCMAG PROGRAMME
  - Once for Scotland advice
  - National consistency
  - Equity of access

- OFF-PATENT USE
  - Reduced cost generic available

- ACCEPTED
  - Routinely accessible via health board formulary processes

- NOT RECOMMENDED
  - Not routinely accessible
  - Individual requests considered

- NOT SUPPORTED
  - Not routinely accessible
  - Individual requests considered

- SUPPORTED
  - Health board review for inclusion in formulary